Key Takeaways
- • Delix Therapeutics closed an oversubscribed $100 million Series C financing, announced November 9, 2026, per Massinvestor and Business Wire.
- • Johnson & Johnson, through its corporate venture arm Johnson & Johnson Innovation JJDC, Inc., and SV Health Investors' Dementia Discovery Fund (DDF) led the round.
- • Existing investors RA Capital, UC Investments, Artis Ventures, OMX Ventures, Dolby Family Ventures and Bail Capital participated, joined by new investors including Adage Capital Management, Hamilton Square Partners Management, Vestal Point Capital and YK Bioventures.
- • Proceeds are earmarked to advance zalsupindole, described as the first neuroplastogen analog of psychedelic compounds, into Phase II development and to fund broader pipeline expansion.
Summary
Bedford, Massachusetts-based Delix Therapeutics, a clinical-stage neuroscience company focused on discovering and developing neuroplastogens, announced the closing of an oversubscribed $100 million Series C financing, according to Massinvestor and Business Wire.
The round was led by Johnson & Johnson, acting through its corporate venture capital organization Johnson & Johnson Innovation JJDC, Inc., alongside SV Health Investors' Dementia Discovery Fund (DDF). Existing backers RA Capital, UC Investments, Artis Ventures, OMX Ventures, Dolby Family Ventures and Bail Capital participated in the financing. The company also added several new investors, including Adage Capital Management, Hamilton Square Partners Management, Vestal Point Capital and YK Bioventures, among others.
According to Business Wire, the proceeds will support advancing zalsupindole into Phase II development, which the company describes as the first true neuroplastogen analog of psychedelic compounds to reach that stage, as well as financing broader pipeline advancement and expansion. The source materials do not disclose the valuation, the price per share, or the specific clinical timelines for the Phase II program.
The participation of a large pharmaceutical company's venture arm alongside a dementia-focused specialist fund and a mix of established life sciences and crossover investors signals institutional confidence in the neuroplastogen platform ahead of mid-stage clinical testing.
The round was led by Johnson & Johnson, acting through its corporate venture capital organization Johnson & Johnson Innovation JJDC, Inc., alongside SV Health Investors' Dementia Discovery Fund (DDF). Existing backers RA Capital, UC Investments, Artis Ventures, OMX Ventures, Dolby Family Ventures and Bail Capital participated in the financing. The company also added several new investors, including Adage Capital Management, Hamilton Square Partners Management, Vestal Point Capital and YK Bioventures, among others.
According to Business Wire, the proceeds will support advancing zalsupindole into Phase II development, which the company describes as the first true neuroplastogen analog of psychedelic compounds to reach that stage, as well as financing broader pipeline advancement and expansion. The source materials do not disclose the valuation, the price per share, or the specific clinical timelines for the Phase II program.
The participation of a large pharmaceutical company's venture arm alongside a dementia-focused specialist fund and a mix of established life sciences and crossover investors signals institutional confidence in the neuroplastogen platform ahead of mid-stage clinical testing.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.